Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab
Clinical Colorectal Cancer · 2024
DOI: 10.1016/j.clcc.2024.05.008 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Chien-Chou Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, ErbB Receptors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Kaohsiung Veterans General Hospital.
Abstract (Originalsprache)
INTRODUCTION: Bevacizumab and antiepidermal growth factor receptor-blocking (anti-EGFR) agents plus chemotherapy are first-line therapies for metastatic colorectal cancer (mCRC). Conversion surgery may improve outcomes; however, the extent to which it explains the difference in mortality rates among treatments is unclear. Herein, we aimed to assess the effects of conversion surgery on survival outcomes of patients with unresectable mCRC treated with bevacizumab and anti-EGFR agents. MATERIALS AND METHODS: This retrospective cohort study included patients with mCRC treated with bevacizumab and anti-EGFR agents as first-line therapy. We estimated the direct and indirect effects of treatments by comparing the mortality risk associated with targeted therapy type. Hazard ratios (HR) and the corresponding confidence intervals (CI) were estimated. Mediation analysis was used to estimate hazard ratio differences, and the proportion mediated. RESULTS: A total of 5,106 patients were included. The natural indirect effect of conversion surgery reduced mortality risk (HR: 0.95; 95% CI, 0.93-0.97), with a mediated proportion of 42% after propensity score adjustment. In subgroup analyses, KRAS wild-type (HR: 0.94; 95% CI: 0.91-0.97), left tumor sidedness (HR: 0.94; 95% CI, 0.91-0.96), and liver resection (HR: 0.95; 95% CI, 0.93-0.98) were associated with reduced risks of mortality. The controlled and total direct effects of targeted therapy were associated with reduced mortality risk in the anti-EGFR-treated group compared to those in the bevacizumab-treated group; however, this effect was not statistically significant. CONCLUSION: Conversion surgery may account for the difference in survival outcomes between users of the anti-EGFR agents and bevacizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; Institute of Clinical Pharmacy and Pharmaceuti…
- Department of Surgery, Division of Colorectal Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Surgery, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electro…
- Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Förderung
- Kaohsiung Veterans General Hospital
Zitieren
APA
Su, C. C., Su, Y. C., Wu, C. C., & Lee, P. T. (2024). Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.05.008
Vancouver
Su CC, Su YC, Wu CC, Lee PT. Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.05.008
BibTeX
@article{Su2024,
author = {Su, Chien-Chou and Su, Yi-Chia and Wu, Chih-Chien and Lee, Pei-Ting},
title = {Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab},
journal = {Clinical Colorectal Cancer},
year = {2024},
doi = {10.1016/j.clcc.2024.05.008}
}
EUVIMED